Literature DB >> 19224840

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

Corey J Langer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19224840     DOI： 10.1200/JCO.2008.20.4859

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

Review 1.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

2.  Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

Authors:  Filippo Pietrantonio; Fotios Loupakis; Giovanni Randon; Alessandra Raimondi; Massimiliano Salati; Dario Trapani; Filippo Pagani; Ilaria Depetris; Giulia Maddalena; Federica Morano; Salvatore Corallo; Michele Prisciandaro; Francesca Corti; Vincenzo Guarini; Alessandro Bocconi; Antonio Marra; Carmen Belli; Andrea Spallanzani; Matteo Fassan; Sara Lonardi; Giuseppe Curigliano; Giovanni Fucà; Maria Di Bartolomeo; Filippo de Braud
Journal:  Oncologist       Date:  2020-05-20

3.  Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit.

Authors:  Chun-Ru Chien; Hung-Jen Chen
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Authors:  Gianmauro Numico; Antonio Trogu; Antonella Cristofano; Alessandro Mozzicafreddo; Giulia Courthod; Pierfrancesco Franco; Nicola Silvestris
Journal:  Support Care Cancer       Date:  2014-05-11       Impact factor: 3.603

Review 5.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

6.  Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer.

Authors:  Aarif Ahsan; Susan M Hiniker; Susmita G Ramanand; Shyam Nyati; Ashok Hegde; Abigail Helman; Radhika Menawat; Mahaveer S Bhojani; Theodore S Lawrence; Mukesh K Nyati
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 7.  How old is "too old" for translational research?

Authors:  Alain Vergnenegre; Romain Corre; Hervé Lena; Hervé Le Caer
Journal:  Transl Lung Cancer Res       Date:  2014-04

8.  Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts.

Authors:  Kenichi Suda; Kenji Tomizawa; Hiroshi Mizuuchi; Simon Ito; Hirokazu Kitahara; Shinichiro Shimamatsu; Mikihiro Kohno; Tsukihisa Yoshida; Tatsuro Okamoto; Yoshihiko Maehara; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Aging Dis       Date:  2012-10-23       Impact factor: 6.745

Review 9.  Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.

Authors:  Matthias Peipp; Michael Dechant; Thomas Valerius
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

10.  Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

Authors:  Meghan Shea; Mark S Huberman; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2016-02-01       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.